Full Text View
Tabular View
No Study Results Posted
Related Studies
Bioavailability of Vagantin® Coated Tablets Relative to an Oral Methantheline Bromide Solution
This study has been completed.
Study NCT01429090   Information provided by University Medicine Greifswald

First Received on September 1, 2011.   Last Updated on September 2, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Neurogenic Bladder
Additional conditions recognized in this trial
Urinary Bladder, Neurogenic
More general conditions related to this trial
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Urinary Bladder Diseases
Urologic Diseases
Interventions listed in this trial
blood sampling
Vagantin®
methantheline solution
Measurement of salivation
Measurement of accommodation
Pupillometry
Additional drug interventions recognized in this trial
Bromides
Methantheline
More general drug interventions related to this trial
Anticonvulsants
Central Nervous System Agents
Cholinergic Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
University Medicine Greifswald
RIEMSER Arzneimittel GmbH


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services